key: cord-0708374-kmmndlrh
authors: Razonable, Raymund R.; Aloia, Nicole C.E.; Anderson, Ryan J.; Anil, Gokhan; Arndt, Lori L.; Arndt, Richard F.; Ausman, Sara E.; Bell, Sarah J.; Bierle, Dennis M.; Billings, Marcie L.; Bishop, Rachel K.; Cramer, Carl H.; Culbertson, Tracy L.; Dababneh, Ala S.; Derr, Amber N.; Epps, Kevin; Flaker, Susan M.; Ganesh, Ravindra; Gilmer, Mary A.; Urena, Eric Gomez; Gulden, Christopher R.; Haack, Tamara L.; Hanson, Sara N.; Herzog, Jenna R.; Heyliger, Alexander; Hokanson, Lex D.; Hopkins, Laura H.; Horecki, Richard J.; Krishna, Bipinchandra Hirisave; Huskins, W. Charles; Jackson, Tammy A.; Johnson, Ryan R.; Jorgenson, Betty; Kudrna, Cory; Kennedy, Brian D.; Klingsporn, Mary K.; Kottke, Brian; Larsen, Jennifer J.; Lessard, Sarah R.; Lutwick, Larry I.; Malone, Edward J.; Matoush, Jennifer A.; Micallef, Ivana N.; Moehnke, Darcie E.; Mohamed, Muhanad; Ness, Colleena N.; Olson, Shelly M.; Orenstein, Robert; Palraj, Raj; Patel, Janki; Paulson, Damian J.; Phelan, David; Peinovich, Margaret T.; Ramsey, Wilford L.; Rau-Kane, Taunya J.; Reid, Kevin I.; Reinschmidt, Karen J.; Seville, Maria Teresa; Skold, Erin C.; Smith, Jill M.; Speicher, Leigh L.; Spielman, Laurie A.; Springer, Donna J.; Sweeten, Perry W.; Tempelis, Jennifer M.; Tulledge-Scheitel, Sidna; Vergidis, Paschalis; Whipple, Daniel C.; Wilker, Caroline G.; Destro Borgen, Molly J.
title: A Framework for Outpatient Infusion of Anti-Spike Monoclonal Antibodies to High-Risk Patients with Mild to Moderate Coronavirus Disease-19: The Mayo Clinic Model
date: 2021-03-09
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.03.010
sha: 84b89be388b7a12cd1f6c3680dea629ecb2548f8
doc_id: 708374
cord_uid: kmmndlrh

The administration of spike monoclonal antibody treatment to patients with mild to moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective spike monoclonal antibody infusion program. Rapid identification of a dedicated physical infrastructure was essential to circumvent the logistical challenges of caring for infectious patients, while maintaining compliance with regulations and ensuring the safety of our personnel and other patients. Our partnerships and collaborations among multiple different specialties and disciplines enabled contributions from personnel with specific expertise in medicine, nursing, pharmacy, infection prevention and control, EHR informatics, compliance, legal, medical ethics, engineering, administration and other critical areas. Clear communication and a culture where all roles are welcomed at the planning and operational tables are critical to the rapid development and refinement needed to adapt and thrive in providing this time-sensitive beneficial therapy. Our partnerships with leaders and providers outside our institutions, including those who care for underserved populations, have promoted equity in the access of monoclonal antibodies in our regions. Strong support from institutional leadership facilitated expedited action when needed, from a physical, personnel, and system infrastructure standpoint. Our ongoing real-time assessment and monitoring of our clinical program allowed us to improve and optimize our processes to ensure that the needs of our COVID-19 patients in the outpatient setting are met.

The administration of spike monoclonal antibody treatment to patients with mild to moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective spike monoclonal antibody infusion program. Rapid in patients at increased risk of clinical progression and hospitalization. [1] [2] [3] However, the administration of anti-spike monoclonal antibodies in the outpatient setting has challenged health care facilities already overwhelmed with the surging number of COVID-19 patients in the hospital, maintenance of testing sites, and the development and rollout of vaccination programs. 4 Healthcare providers are hesitant to prescribe these monoclonal antibodies as medical society guidelines from the National Institutes of Health (NIH) 5 , Infectious Disease Society of America (IDSA) 6 , and Pediatric Infectious Diseases Society (PIDS) 7 have not endorsed their routine use due to modest efficacy demonstrated in the clinical trials. Furthermore, patients are either unaware of the availability of these products (and do not actively seek out treatment) or are concerned about its investigational J o u r n a l P r e -p r o o f nature. Moreover, the logistical challenges of administering outpatient monoclonal antibody infusions to contagious COVID-19 patients have curtailed their widespread use. As such, a dedicated facility that can serve the needs of these patients, while adhering to infection prevention and control (IPAC) policies to limit potential exposures to medical personnel and the community is vital.

Addressing these unique challenges, Mayo Clinic developed a dedicated clinical program for safely administering anti-spike monoclonal antibodies to patients. The multidisciplinary program started to administer these therapies as soon as the first shipment of bamlanivimab arrived at its facilities on November 19, 2020. By February 19, 2021, Mayo Clinic had infused anti-spike monoclonal antibodies to more than 4,100 patients across its sites in Arizona, Florida, Minnesota, and Wisconsin.

In this report, we describe our framework for the successful implementation of this program. The essential components are listed in Table 1 and the details of our processes that incorporate these components are shown in Figure 1 . We hope that our processes can serve as a model for the creation of dedicated infusion therapy practices for patients with COVID-19, and other potentially infectious pathogens. The lessons we learned can guide others in developing similar programs within their healthcare institutions. The US FDA has issued separate EUAs to three neutralizing monoclonal antibody preparations, bamlanivimab, casirivimab-imdevimab, and bamlanivimab-etesevimab, for early treatment of high-risk patients with mild to moderate COVID-19 in the outpatient setting. [1] [2] [3] The

EUAs are based on preliminary data from early phase clinical trials that separately compared the monoclonal antibodies with placebo, and showed reductions in viral load and potentially the need for hospitalizations or emergency room visits.

In an interim analysis of a phase 2 trial that randomized 452 patients to receive an intravenous infusion of bamlanivimab (of varying doses) versus a placebo, the percentage of patients who required hospitalization or emergency room visit by day 29 was lower (1.6% of 309 patients) in the bamlanivimab cohort compared to placebo (6.3% of 143 patients). 2 In a post hoc analysis among high risk patients (≥65 years of age or BMI ≥35), hospitalization rate was lower (4% of 95 patients) in the bamlanivimab group compared to placebo (15% of 48 patients). 2 In a subsequent analysis of this ongoing clinical trial, the patients who received the combination of balmanivimab and etesevimab had a significant reduction in viral load when compared to those who received bamlanivimab monotherapy. 3 In an interim analysis of a phase 1-2 trial of 275 patients, the use of casirivimab and imdevimab was also associated with reduction in viral load especially among patients with high initial viral load and negative SARS-CoV-2 serology. 1 In the seronegative population, the rate of hospitalization was reduced from 15% (among placebo group) to 6% (among those who received casirivimab and imdevimab), although this difference was not statistically significant. 1 

The US FDA granted EUA for bamlanivimab (700 mg dose) on November 9, 2020, casirivimab (1200 mg dose)-imdevimab (1200 mg dose) combination on November 21, 2020, and bamlanivimab (700 mg dose)-etesevimab (1400 mg dose) combination on February 9, 2021, for early treatment of high-risk patients with mild to moderate COVID-19 in the outpatient setting. Subsequently, the US government distributed monoclonal antibodies to the states that are tasked with allocation and distribution to healthcare facilities within their jurisdictions. However, there have been many factors that markedly limited the widespread use of these products (as discussed throughout this article), resulting in a large stockpile of unused monoclonal antibody supplies.

Because spike monoclonal antibody therapies are given intravenously, they require eligible patients to leave the confines of their home quarantine in order to receive infusions in healthcare facilities. The infusions may also be provided in long-term care facilities and nursing homes that are able to administer the drugs. Information Technology (IT) analysts rapidly developed electronic order sets for these monoclonal antibodies. IT teams leveraged the EHR to create an algorithm to automatically identify patients with new diagnosis of COVID-19 (based on testing) who fulfill the criteria for allocation (see below). EHR experts assisted the monoclonal antibody team by integrating a documentation field for date of symptom onset in the COVID-19 intake call for testing to populate the algorithm for our allocation process. This was helpful in our clinical review of patients, especially those who are new to our health system with an incomplete medical record.

EHR experts also developed a Monoclonal Antibody Treatment Registry for all patients who are eligible, infused, or who declined infusions. This facilitated the task of reporting our data to our state departments, and assisted in real-time review to optimize our processes for patient education and consenting, improve the logistics of our program and assessment of clinical outcomes.

Per the FDA EUAs, bamlanivimab, casirivimab-imdevimab, and bamlanivimabetesevimab may only be given for emergency use to a select group of high-risk individuals. 17 These include patients who are 65 years of age and older, have diabetes, have a BMI greater than or equal to 35, have chronic kidney disease, and/or those with compromised immune systems, J o u r n a l P r e -p r o o f either from disease or from use of immunosuppressive agents. Patients 55 years and older may also be eligible if they have hypertension, cardiovascular disease, chronic obstructive pulmonary disease, or other chronic respiratory disease. Children 12 years of age and older and weighing at least 40 kg are eligible if they meet criteria ( Table 1) . Our partnership with EHR informatics afforded us the ability to quickly screen and identify eligible patients based on the EUAs and state guidance.

Identifying high-risk patients quickly is critical in order to offer them infusion of the monoclonal antibodies as early as possible and within ten days of symptom onset. Data suggests that monoclonal antibodies are more efficacious if given prior to the development of endogenous antibodies. 1 However, we learned that patients are often unaware of these therapies, and accordingly, they do not actively seek out treatment. For high-risk patients who are aware of these treatments, many decline infusions during the early course of their illness when they only experience minimal symptoms. However, by the time patients experience a significant increase in symptom burden, they may no longer be eligible for infusion based on clinical severity criteria. Some patients voiced concern about the investigational status of monoclonal antibodies, the potential for drug-drug interactions, or cost of treatment, while others refused the therapies because their local providers are skeptical to recommend them due to limited efficacy data. 

A multidisciplinary MATRx team was created to tap into the clinical and administrative expertise of multiple providers and healthcare personnel ( Table 1) . Many members are also part of the CFCT, which ensured coordination between monitoring and treatment groups. 14, 15 The

MATRx clinical team developed the process of drug allocation, based on the guidance from the FDA and our states' Departments of Health and Human Services, with input from medical ethics and legal colleagues to ensure a fair and equitable process. Since the start of our program, the MATRx team convenes daily to review and discuss the list of COVID-19 patients, and allocate J o u r n a l P r e -p r o o f the medications to eligible patients across our sites. During this meeting, the multidisciplinary team also discusses issues that emerged and optimizes our processes of program implementation.

We developed partnerships with clinical practice providers and teams through education on anti-spike monoclonal antibodies and the eligibility criteria for infusion. Some providers have expressed hesitancy in proactively advocating for use in their patients due to lack of solid clinical data, and the statements of caution from NIH, IDSA and PIDS. [5] [6] [7] Our MATRx team developed education materials on monoclonal antibodies that were disseminated through electronic mail communication, virtual practice meeting updates, electronic bulletins, and the Ask Mayo Expert online clinical reference and decision making platform. Our MATRx team also communicated our real-world outcomes, with updates provided to institutional leadership and local providers through Grand Rounds and clinical practice forums.

We developed partnerships with leaders and providers who practice outside our walls.

This includes community and county hospitals, nursing homes, assisted living communities and long-term care facilities, and those who care for underserved and underrepresented populations.

Because patients tested at other facilities are not automatically pulled into our daily report, we developed a pathway for external providers to refer their patients to our program. Self-referred patients are considered. This was especially important in regions that lacked other health systems performing monoclonal antibody infusions, as it created a pathway for patients in those regions to receive treatment that was otherwise unavailable to them. Our MATRx clinical review team quickly screens all patient and provider referrals, verify medical information, and determine eligibility based on the FDA EUA criteria.

Our provider and nursing teams contact all patients identified as eligible in order to provide education about monoclonal antibodies, inform about the process of infusions, and obtain verbal consent for infusion (Figure 1, Supplementary Materials A and B) . Language interpreters are available to assist patients or their legally authorized representatives. Our team emphasizes to the patients that monoclonal antibody therapies are free of charge, and that we Our ITC has well-established processes in providing medications to patients outside the hospital. We partner with ITC leaders, providers, nurses and pharmacists to help implement our outpatient monoclonal antibody infusions. We leverage inpatient pharmacies to prepare the monoclonal antibodies for all patients scheduled for infusion each day. At some locations, logistical barriers needed to be overcome since the COVID-19 infusion centers are not physically connected to the hospital pharmacy. In these situations, our pharmacy team prepares the medications for same-day delivery to our infusion facilities, and having an efficient drug delivery service allows us to accommodate patients who are scheduled for infusion within hours of consenting. Upon patient arrival, but prior to infusion, our nursing team screens patients to ensure that they still have mild to moderate COVID-19 symptoms. If they have worsened clinically (e.g., if they now require oxygen supplementation), the infusions are cancelled and patients are directed to receive further care at our emergency department. For patients who are still eligible for the infusion, our nurses monitor them for adverse effects during and for one hour after completion of therapy. The infusion unit is stocked with medications that can be used to address potential hypersensitivity and other adverse events.

Our infusion therapy team, which consists of nursing and desk operations, is critical in ensuring adherence to IPAC policies and practices. Personal protective equipment, including J o u r n a l P r e -p r o o f gown, mask and gloves, were used by all staff in direct contact with the patient. We have no report of staff exposure by strictly adhering to IPAC procedures. Upon arrival to the infusion center, patients call the desk personnel who will escort them from their vehicle directly to the infusion units, in order to prevent them from lingering in hospital and clinic premises, minimizing the potential for exposure of other patients, visitors and healthcare personnel.

Patients are required to wear face masks at all times. After their infusion appointment, the patients are escorted back out of the building to their private transportation. The use of public transportation was specifically discouraged. For many patients who are residents of nursing homes and long-term care facilities that do not have the ability to provide infusions, or are unable to safely travel to our infusion centers, our mobile therapy team travels to infuse them at their facilities. 16 Supported by physician leaders, our infusion therapy team serves as a contact for patients to report any issues after they leave the infusion centers. Adverse effects are reported electronically to the FDA by physician leaders utilizing the MedWatch form. Patients enrolled in Remote Monitoring Program and the CFCT nursing program continues to be monitored through telemedicine.

The interplay among various components of the monoclonal antibody allocation and administration workflow is depicted in Figures 1 and 2 . Adjustments to this workflow were made across our infusion sites based on federal, state and local regulations. A Monoclonal Antibody Treatment Registry of all screened and infused COVID-19 patients serve our aim to J o u r n a l P r e -p r o o f continually examine and refine our clinical program, improve the quality of care we provide, and assess our outcomes. Continuous quality improvement using a Plan-Do-Study-Act framework is utilized to provide assessment of the process and target improvement interventions. The daily MATRx meeting facilitates efficient communication between relevant stakeholders. This provides a platform to review eligibility and patient infusion volumes, provide feedback on process updates, and identify topics that require escalation to senior leadership. Follow up mechanism, including call back number for reporting of adverse effects Real-time and systematic review of outcomes a High risk adolescents included individuals with any of the following underlying conditions: poorly controlled Type I diabetes mellitus (most recent HbA1C >8%) or Type II diabetes mellitus; end-stage renal disease receiving dialysis (peritoneal or hemodialysis); allogeneic stem cell transplant within the previous 3 months; solid organ transplant within the previous 3 months or currently receiving treatment for rejection; high-risk ALL with receipt of induction or consolidation chemotherapy during the previous 4 weeks; AML with receipt of any chemotherapy during the previous 4 weeks; primary or acquired immunodeficiency with significant cellular immunodeficiency; receipt of immunosuppression with biologic agents such as tumor necrosis factor-alpha (TNF-α) antagonists (e.g., adalimumab, certolizumab, infliximab, etanercept, and golimumab), anti-B-lymphocyte monoclonal antibodies (e.g., rituximab), anti-Tlymphocyte monoclonal antibodies (eg, alemtuzumab);or daily corticosteroid therapy at a dose ≥20 mg (or >2 mg/kg/day for patients weighing <10 kg) of prednisone or equivalent for ≥14 days; severe obesity, defined as at or above 120% of the 95th percentile; sickle cell disease with ≥1 hospitalization for a SCD-related complication in the previous 3 years; chronic lung disease requiring day-time home supplemental oxygen or ventilation; severe asthma or poorly controlled asthma; neuromuscular disease with home respiratory support (CPAP, BiPAP, Oxygen, Cough Assist); heart failure and currently listed for cardiac transplant; congenital heart disease with single ventricle physiology and heart failure, defined as a systemic ventricle EF <30%, or the presence of protein-losing enteropathy or plastic bronchitis. 

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents

A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting

Remdesivir for the Treatment of Covid-19 -Final Report

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Clinical Guidance and the Delivery of Care for Patients With Coronavirus Disease 2019

Telemedicine Consultations and Follow-up of Patients With COVID-19

Mobile Unit Overcomes the Challenges to Monoclonal Antibody Infusion for COVID-19 in Skilled Nursing Facilities

An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19

The authors would like to express appreciation to all the patients and their legally authorized representatives for trusting us for their medical care, our nurses and providers who contacted our patients and provided education, our desk operations who assisted in the care of our patients, our personnel who transported medications to our off-site infusion units, and for safely transporting our mobile infusion teams to nursing homes and long-term care facilities. The authors also thank Information Technology experts who rapidly built our Monoclonal Antibody